10-K: Medinotec Reports Soaring Revenue and Profitability in Fiscal 2025, Driven by US Trachealator Sales and New Distribution Deals

Medinotec, Inc. announced a significant financial turnaround in its fiscal year ended February 28, 2025, reporting an 81.5% surge in revenue and a shift from a net loss to a substantial net income, primarily fueled by new distribution agreements in South Africa and successful commercialization of its Trachealator device in the United States.

Summary

• Medinotec, Inc. reported total revenue of $9,113,607 for the fiscal year ended February 28, 2025, an 81.5% increase from $5,020,391 in the prior year.
• The company achieved a net profit of $2,159,473 in fiscal 2025, a significant improvement from a net loss of $404,688 in fiscal 2024.
• Gross profit for fiscal 2025 was $4,860,786, with the gross margin improving to 53% from 49% in the previous fiscal year.
• Sales in the United States, primarily from the Trachealator device, reached $678,105 in fiscal 2025, representing 7% of total sales, up from $553,967 (11% of total sales) in the prior year.
• The company fully impaired a note receivable of $642,012 from Innovative Outcomes on November 30, 2023, due to a material change in strategic focus, though Innovative Outcomes remains liable for payment.
• As of February 28, 2025, Medinotec had strong liquidity with cash reserves of $2,769,686 and working capital of $4,918,139.
• Material weaknesses in internal control over financial reporting were identified, including a lack of written documentation, insufficient segregation of duties, and an underdeveloped control environment.
• The company's related party loan from Minoan Medical Proprietary Limited decreased to $940,001 as of February 28, 2025, from $1,769,688 in the prior year.

Sentiment

Score: 7

Explanation: The company demonstrated strong financial performance with significant revenue growth and a return to profitability, driven by successful product commercialization and new distribution agreements. However, material weaknesses in internal controls, high customer concentration, and geopolitical risks in South Africa temper the overall positive outlook, warranting a cautious but optimistic sentiment.

Positives

• Revenue increased by 81.5% year-over-year, reaching $9,113,607 in fiscal 2025, indicating strong market penetration and demand.
• The company successfully transitioned from a net loss of $404,688 in fiscal 2024 to a net profit of $2,159,473 in fiscal 2025, demonstrating improved financial health.
• Gross margin improved from 49% to 53%, reflecting increased sales efficiency and a favorable sales mix of higher-margin products.
• Successful commercialization of the Trachealator in the U.S. market contributed significantly to revenue growth, with sales reaching $678,105.
• FDA clearance for the Aortic Valve Dilation Balloon Catheter (OutFlo) was obtained on March 11, 2025, post-fiscal year end, signaling future product commercialization potential.
• Multiple patents for the Trachealator have been granted in key regions including the USA, China, South Korea, and South Africa, with intentions to grant in the EU and acceptance in Australia, strengthening intellectual property protection.
• The company maintains a strong liquidity position with $2,769,686 in cash and $4,918,139 in working capital, providing financial flexibility.
• The manufacturing facility operates below maximum capacity, allowing for increased production without significant additional capital investment.
• The related party loan from Minoan Medical Proprietary Limited was significantly reduced by $829,687 in fiscal 2025, strengthening the balance sheet.

Negatives

• A note receivable of $642,012 from Innovative Outcomes was fully impaired due to a material change in strategic focus, indicating a loss of expected revenue streams from that partnership.
• The company faces high customer concentration risk, with 88% of its total revenue in fiscal 2025 derived from a single customer, DISA Life Sciences, in South Africa.
• Material weaknesses were identified in internal control over financial reporting, including a lack of formal written documentation, insufficient segregation of duties, and an underdeveloped control environment.
• The company relies on a limited number of subcontractors for manufacturing, assembly, packaging, and production testing, posing supply chain risks.
• A substantial portion of sales relies on third-party distribution agreements, over which the company has limited control regarding marketing efforts.
• The company's officers and directors are located outside the U.S., which may complicate the enforcement of legal judgments in the United States.
• Management acknowledges limited experience in managing a public company, which could pose operational and compliance challenges.
• The company's common stock is subject to 'Penny Stock' rules, which may reduce trading activity and liquidity for investors.
• The company does not anticipate paying cash dividends in the foreseeable future, limiting investor returns to stock price appreciation.

Risks

• Substantial leverage and debt service obligations could adversely affect the business, with current liabilities of $1,505,047 and long-term liabilities of $1,033,097 as of February 28, 2025.
• The company may need additional financing for expansion plans, and limitations on obtaining such capital could materially affect operations and results, potentially leading to dilution for stockholders.
• Future changes in financial accounting standards or taxation rules, especially across multiple operating territories, may cause adverse or unexpected revenue fluctuations.
• Consolidation in the healthcare industry could lead to increased competition and pressure for price concessions, adversely affecting revenues and profitability.
• Healthcare industry cost-containment measures by third-party payers could result in reduced sales of medical devices and components.
• The continuing development and marketing of products depend on maintaining strong relationships with external healthcare professionals, and failure to do so could negatively impact financial success.
• Products in the development pipeline may not come to market or fail to commercialize due to various factors, including production costs, market acceptance, or safety/efficacy failures.
• Operating in a highly competitive industry with larger, more resourced players may hinder the company's ability to compete effectively and gain market share.
• Reduction or interruption in supply from sole suppliers or manufacturing difficulties due to geopolitical tensions, natural disasters, or power outages could adversely affect operations and product sales.
• Reliance on the proper function, security, and availability of IT systems and data, with potential breaches or cyber-attacks materially affecting business, reputation, and financial condition.
• Exposure to foreign exchange risk due to operations in developing countries with volatile currencies, potentially causing adverse revenue fluctuations.
• High sales and accounts receivable concentration risk, with 88% of revenue from a single customer, increasing vulnerability to contract changes or disruptions.
• The company's insurance program may not be adequate to cover future losses, increasing exposure to unanticipated claims.
• Future growth is dependent on new product development and line extensions, which are expensive, time-consuming, and may not result in commercially viable products.
• Failure to maintain proper and effective internal controls could impair the ability to produce accurate and timely financial statements, harming operating results and investor confidence.
• Limited experience in marketing and sales, particularly in the life science market and internationally, may hinder planned growth.
• Reliance on a limited number of third-party subcontractors for manufacturing and testing poses risks of supply disruption, quality control issues, and increased costs.
• Dependence on distributing commodity medical products for multinational manufacturers means failure to maintain these relationships could harm the business.
• The company depends on senior management personnel, and the inability to retain or replace them could harm the business.
• Concentrated voting power by Dr. Gregory Vizirgianakis and Stavros Vizirgianakis (81% combined) allows them to influence corporate matters, potentially not aligning with minority shareholder interests.
• Officers and directors are located outside the U.S., making it difficult to effect service of process and enforce legal judgments in the U.S.
• Extensive medical device regulation (FDA, CE Mark) may impede or hinder product approval, or result in recalls/seizures of approved products.
• Modifications to products may require new regulatory clearances, potentially leading to marketing cessation or recalls until approvals are obtained.
• Potential liability if the FDA or other U.S. enforcement agencies determine engagement in off-label promotion or dissemination of false/misleading materials.
• Healthcare policy changes, including cost-containment measures and reimbursement reforms, may materially affect the company's ability to sell products profitably.
• Subject to environmental laws and regulations and the risk of environmental liabilities, violations, and litigation.
• Claims and litigation, including product liability claims, could distract management, result in significant liability, or damage the brand.
• Failure to comply with laws and regulations relating to reimbursement of healthcare goods and services may subject the company to penalties and adversely impact its reputation.
• Inability to effectively protect intellectual property rights (patents, trademarks, trade secrets) could lead to costly litigation or compromise business.
• Security breaches, loss of data, and other disruptions to IT systems could compromise sensitive information, leading to liability and reputational harm.
• Changes in tax laws or exposure to additional income tax liabilities in various jurisdictions could materially impact financial results.
• Failure to comply with anti-corruption laws (e.g., FCPA) could result in civil/criminal sanctions and disrupt business.
• Laws and regulations governing international business operations, including U.S. economic sanctions and trade restrictions, could adversely impact operations.
• As an Emerging Growth Company, reliance on certain disclosure exemptions may make common stock less attractive to investors.
• As a Smaller Reporting Company, scaled disclosures may result in less company information for investors compared to larger public companies.
• Geopolitical and trade risks, including U.S. tariffs on South African imports and potential revocation of AGOA benefits, could significantly impact export costs and market access.
• Unstable power supply in South Africa (load-shedding) may cause frequent production halts, despite backup generators.
• Political instability in South Africa, including violent civil unrest, may affect the company's ability to operate effectively and investor confidence.
• Broad-based Black Economic Empowerment (BEE) requirements in South Africa may restrict growth opportunities and limit the ability to attract key talent.
• South African authorities may disallow or delay the transfer of funds from South Africa to the United States due to exchange control regulations, potentially impacting U.S. operations funding.
• South Africa's grey-listing by the FATF (Financial Action Task Force) could lead to higher levels of customer due diligence by foreign financial institutions, potentially increasing costs of cross-border business and making capital raising harder.

Future Outlook

Medinotec anticipates continued growth in sales and marketing expenses as it expands into new territories, particularly in the United States, and focuses on maintaining and obtaining product registrations. The company plans to constantly innovate and enhance its product range, with a strategic shift towards growing its product offerings and making strategic acquisitions rather than further expanding production facilities. While current operations are self-funded, the company acknowledges that major strategic initiatives or significant future R&D efforts may require additional external capital, and it will continue to explore various financing options and strategic partnerships.

Management Comments

• "The FDA approval that was granted for the Trachealator in November 2021 together with the concluded private placement allowed for the roll out in the United States which started during the 2024 fiscal year."
• "We are finalizing multiple patent applications in several territories, which we believe will give us the ability not only to maintain our intellectual property but also to market our products aggressively."
• "The Groups expectation is to reduce reliance on the South African markets for customers and accounts as the Group endeavors to expand and enter into international first world markets."
• "Our objective is to become one of the significant industry players within the next five years."
• "We focus on building and operating facilities with low operating costs to enable us to better manage market downturns."
• "The Company has sufficient cash reserves and working capital to fund the roll-out in the market of the United States, including new research and development activities, as well as marketing and sales functions."
• "Management is actively engaged in addressing the material weaknesses in internal control over financial reporting identified as of February 28, 2025."

Industry Context

Medinotec operates in a highly competitive global medical device market, characterized by rapid technological advancements and scientific discoveries. The industry is seeing a strong drive towards minimally invasive procedures at lower costs, which aligns with Medinotec's product focus. However, the market is dominated by large multinational players, and increasing price sensitivity is a key competitive factor due to managed care, industry consolidation, and declining reimbursement rates. North America is identified as a dominant market for medical supplies and investment, driven by robust regulation and growing awareness of alternative treatments. The company's strategy of leveraging a low-cost operating structure in South Africa positions it to compete on price, while its focus on niche products in cardiology and respiratory interventions targets specialized, high-value segments of the market.

Comparison to Industry Standards

• Medinotec competes with major multinational medical device companies such as Johnson & Johnson, Boston Scientific, Cook Medical, Cordis, B. Braun, Teleflex, Medtronic, Merit Medical, Endotec, Conmed, and Cadence, which generally possess significantly more capital, larger R&D capabilities, and more extensive distribution systems.
• The company's gross margin of 53% in fiscal 2025 is a strong performance indicator, especially for a medical device manufacturer, though direct comparisons to specific industry benchmarks for niche players are not provided.
• Medinotec's reliance on a single customer (DISA Life Sciences) for 88% of its revenue in South Africa represents a significant customer concentration risk, which is atypical for larger, more diversified industry leaders.
• The company's focus on developing and manufacturing niche products for minimally invasive procedures in interventional cardiology and endolaryngeal endoscopy aligns with a growing and high-value segment of the global medical device market.
• Obtaining FDA approval for the Trachealator and CE Mark for most products demonstrates compliance with stringent international regulatory standards, comparable to those met by established industry players for market entry in major developed economies.

Corporate Governance

Legal Proceedings

• As of the date of this Annual Report, there is no known material litigation or claims against the Company.
• The company may become involved in various legal proceedings in the ordinary course of its business and may be subject to third-party infringement claims.
• The company may be liable if the FDA or other U.S. enforcement agencies determine it has engaged in off-label promotion of its products or disseminated false or misleading labeling or promotional materials.
• The company is subject to environmental laws and regulations and faces the risk of environmental liabilities, violations, and litigation.
• Failure to comply with laws and regulations relating to reimbursement of healthcare goods and services may subject the company to penalties and adversely impact its reputation.
• Quality problems and product liability claims could lead to recalls or safety alerts, reputational harm, adverse verdicts, or costly settlements.
• The company may not be able to effectively protect its intellectual property rights, potentially leading to costly litigation.
• Security breaches, loss of data, and other disruptions could compromise sensitive information, exposing the company to liability and harming its reputation.
• The company has taken legal action to recover the impaired note receivable from Innovative Outcomes.

Related Party Transactions

• Minoan Medical Proprietary Limited, controlled by CEO Dr. Gregory Vizirgianakis, provided an unsecured loan of $940,001 to DISA Medinotec, which was assumed by Medinotec Inc. after acquisition. The loan carries interest at the prevailing prime lending rate (11.00% at Feb 28, 2025) and can be settled in cash or equity.
• Minoan Capital Proprietary Limited, also controlled by CEO Dr. Gregory Vizirgianakis, provided an unsecured, interest-free loan of $276 to Medinotec Capital Proprietary Limited.
• DISA Medinotec Proprietary Limited leases commercial buildings from Minoan Capital Proprietary Limited, with rent paid totaling $51,759 in fiscal 2025. The terms are deemed market-related.
• DISA Life Sciences Proprietary Limited, a South African sub-distributor, accounted for 88% of the company's total revenue in fiscal 2025 (86% in fiscal 2024), indicating significant customer concentration.
• Dr. Gregory Vizirgianakis (CEO, President, Secretary, Director) and Pieter van Niekerk (CFO, Treasurer, Director) are executives of both Medinotec Inc. and its South African subsidiaries, Medinotec Capital Proprietary Limited and DISA Medinotec Proprietary Limited.
• Stavros G. Vizirgianakis, a director and brother of Dr. Gregory Vizirgianakis, holds a significant beneficial ownership of 40.5% in Medinotec Inc., similar to Dr. Gregory Vizirgianakis's 40.5%.

Stakeholder Impact

• **Shareholders**: Experience potential dilution from future equity offerings, face stock price volatility due to market factors and internal control weaknesses, and will not receive dividends in the foreseeable future. The concentrated voting power of the founders may limit the influence of minority shareholders. Enforcement of legal judgments against non-U.S. officers/directors may be difficult.
• **Employees**: The company prioritizes attracting and retaining competent personnel in a competitive labor market. Political instability and load-shedding in South Africa could impact their work environment and operational continuity.
• **Customers**: Benefit from the company's commitment to innovation, high-quality products, and extensive distribution network. However, industry cost-containment measures and potential product quality issues could affect product availability or pricing.
• **Suppliers**: The company's reliance on a limited number of subcontractors for key components creates a dependency, and any failure in the supply chain could impact the company's ability to fulfill orders.
• **Creditors**: The company's substantial leverage and debt service obligations, though manageable with current cash reserves, pose a risk. The related party loan terms and potential for equity settlement are notable.
• **Regulatory Bodies**: The company is subject to extensive and evolving medical device regulations (FDA, CE Mark, SAHPRA), requiring significant compliance costs and posing risks of penalties for non-compliance.

Next Steps

• Continue to add dedicated sales team members in the United States as sales grow and regulatory hurdles are cleared.
• Finalize multiple patent applications in several territories to maintain intellectual property and aggressively market products.
• Replicate the successful South African sales network in the US market.
• Reduce reliance on South African markets for customers and accounts by expanding into international first-world markets.
• Secure investment opportunities and additional distributor relationships throughout North America.
• Continue to ensure quality manufacturing of current products and ongoing investment into proprietary intellectual property.
• Pursue planned strategic bolt-on acquisitions to ensure financial stability and smooth integration of new businesses.
• Increase presence and product offering in specialty product end-markets through new product acquisitions and distributorships.
• Further develop value-added capabilities by growing product offerings, improving supply chain management, upgrading IT, and enhancing customer service.
• Optimize product mix and continue continuous improvement efforts to keep operating costs low and increase production/distribution efficiency.
• Strategically position logistic capabilities and supply chain network to meet customer needs, including exploring new distribution centers.
• Maintain balance sheet strength and flexibility to manage industry downturns and pursue growth opportunities.
• Carry sufficient levels of inventory to meet product delivery needs of customers.
• Continue investment into healthcare training and academic development in southern Africa to retain necessary skills.
• Complete various networks and obtain regulatory approvals to export and distribute products to countries such as Australia, Japan, and China.
• Ensure compliance with the new Medical Device Regulation (MDR) 2017/745 for remaining products, with Technical Files currently under review by DEKRA.
• Obtain required FDA certification for two cardiac catheters to enable marketing and sales in the US.
• Begin formal documentation of key internal control processes and procedures, enhance segregation of duties, and adopt a formal Code of Business Conduct and Ethics to remediate identified material weaknesses.
• Monitor foreign exchange risks and assess hedging strategies to mitigate currency fluctuations.
• Explore opportunities for alternative funding sources, including strategic partnerships, grants, and government incentives, to support expansion and product development initiatives.
• Assess potential tax impacts if the company's consolidated revenue exceeds the 750 million Euro threshold for Pillar Two global minimum tax rules.

Key Dates

Recommendation

Keywords

Medical Devices, Healthcare Technology, Trachealator, Coronary Catheters, Interventional Cardiology, Respiratory Interventions, FDA Approval, CE Mark, South Africa, United States Market, Medical Device Manufacturing, Distribution Agreements, SEC Filing, 10-K, Financial Results, Corporate Governance, Risk Management, Intellectual Property, Minimally Invasive Procedures, Emerging Growth Company